Unsurprisingly, Fostamatinib, an US FDA-approved SYK inhibitor, has been currently developed as therapies for several autoimmune diseases, including immune thrombocytopenia (ITP), rheumatoid arthritis (RA) [25], and preclinical study in SLE [26] the impacts on lupus of this commercially available drug might be interesting. Here, SYK is linked to autoimmune thrombocytopenic purpura.